What Is Lung Cancer? Types, Symptoms & Stages

Lung cancer is a disease in which cells in the lung tissue grow uncontrollably, forming tumors that can invade nearby structures and spread to distant organs. It is the leading cause of cancer death among both men and women worldwide, a status it reached over the past century as tobacco use became widespread.¹ But “lung cancer” is not one disease. It is a family of cancers that differ in how they look under a microscope, how fast they grow, what genetic mutations drive them, and how doctors treat them. Understanding the types, the symptoms that show up (and when), and the staging system that guides treatment decisions gives you a much clearer picture of what a diagnosis actually means.

The Two Main Categories

Doctors split lung cancer into two broad groups based on how the cancer cells look under a microscope. Non-small cell lung cancer (NSCLC) accounts for roughly 80 to 85 percent of all cases. Small cell lung cancer (SCLC) makes up most of the remainder. The distinction matters because the two behave very differently. NSCLC tends to grow more slowly and is more likely to be caught at a stage where surgery can help. SCLC, by contrast, is aggressive: it grows fast, spreads early, and is usually treated with chemotherapy and radiation rather than surgery.

Within those two groups are several subtypes, each with its own personality. Thinking of “lung cancer” as a single thing is a bit like thinking of “infection” as one illness. The subtype shapes the prognosis, the treatment options, and even the symptoms you might experience.

Non-Small Cell Lung Cancer Subtypes

NSCLC breaks down into three main subtypes. Adenocarcinoma is the most common, particularly in people who have never smoked. It typically starts in the outer regions of the lung, in the cells that line the small air sacs. On imaging, adenocarcinoma often shows up as a ground-glass opacity or a patchy shadow, patterns that can sometimes mimic pneumonia or scarring.² Because of its peripheral location, adenocarcinoma can grow quietly for a while before causing obvious symptoms like coughing or chest pain.

Squamous cell carcinoma tends to arise in the central airways, closer to where the bronchial tubes branch. It is more strongly linked to smoking and is more common in men. Compared with adenocarcinoma, squamous cell tumors tend to be larger at diagnosis, more likely to cause cough and hemoptysis (coughing up blood), and more prone to infections in the obstructed lung tissue downstream of the tumor.² Researchers have traced the molecular roots of squamous cell carcinoma through a series of changes in the bronchial lining of smokers, essentially a slow accumulation of genetic damage over years of exposure.³

Large cell carcinoma is the least common NSCLC subtype. It can appear anywhere in the lung and tends to grow and spread quickly. When it metastasizes, it has a particular tendency to land in the adrenal glands, small hormone-producing organs that sit on top of the kidneys.⁴

Small Cell Lung Cancer and Neuroendocrine Tumors

SCLC originates from neuroendocrine cells, a rare cell type scattered through the lung lining. These cells normally help regulate airway function, and the cancer that arises from them retains some of their characteristics, including the ability to produce hormones and other signaling molecules. SCLC is classified as a high-grade neuroendocrine tumor, meaning it is fast-growing and highly malignant.⁵ It is overwhelmingly associated with heavy smoking.

Large cell neuroendocrine carcinoma (LCNEC) is a rarer cousin that shares SCLC’s aggressive behavior and poor prognosis.⁶ Both SCLC and LCNEC are driven by specific transcription factors that push cells down the neuroendocrine path. Research has revealed that SCLC tumors are not all alike: some express high levels of neuroendocrine markers and certain master regulators, while others have lost most of those markers entirely, creating distinct subtypes within SCLC itself.⁷ This internal diversity helps explain why some SCLC tumors respond differently to treatment than others.

Carcinoid Tumors of the Lung

On the gentler end of the neuroendocrine spectrum sit carcinoid tumors. These are low-grade or intermediate-grade neuroendocrine tumors that grow much more slowly than SCLC. They split into typical carcinoids, which make up about 80 percent of cases, and atypical carcinoids, which are somewhat more aggressive.⁸ Carcinoids are more evenly distributed between men and women and are not strongly tied to smoking.

About two-thirds of patients with pulmonary carcinoids have symptoms at diagnosis, most commonly coughing up blood, shortness of breath, or a persistent cough.⁸ Only a small fraction, around 8 percent, develop carcinoid syndrome, the flushing, diarrhea, and wheezing caused by hormones the tumor releases. The prognosis for typical carcinoids is generally good after surgical removal. Atypical carcinoids are a different story: in one institutional series, three-quarters of atypical carcinoid patients already had positive lymph nodes at diagnosis, compared with just 2 percent of typical carcinoid patients.⁸

Symptoms and Warning Signs

Lung cancer is notoriously quiet in its early stages. Many people have no symptoms at all until the tumor is advanced. When symptoms do appear, they overlap heavily with common, less serious conditions like bronchitis or allergies, which is one reason diagnosis is often delayed.

The symptoms most associated with lung cancer, based on a systematic review pooling data from multiple studies, are:

Ironically, more advanced lung cancers tend to be diagnosed faster than early-stage ones. In a prospective study tracking patients from their first symptom to diagnosis, people with late-stage cancer had a median diagnostic interval of about 106 days, compared with 168 days for early-stage cancer.¹¹ The reason is straightforward: advanced tumors cause louder, more alarming symptoms that push patients and doctors to act quickly, while early tumors may produce only a nagging cough that gets attributed to something benign for months.

Paraneoplastic Syndromes

Some lung cancers cause symptoms that have nothing to do with a mass in the chest. These are called paraneoplastic syndromes, and they happen when cancer cells produce hormones, antibodies, or other signaling molecules that affect distant parts of the body.¹² The effects are not caused by the tumor pressing on anything or by metastasis; instead, the cancer essentially tricks the body’s own systems into misbehaving.

SCLC is especially prone to these. Because it arises from hormone-producing neuroendocrine cells, SCLC can secrete excess hormones that cause endocrine problems, or trigger antibodies that attack the patient’s own nervous system.¹³ Examples include a syndrome of inappropriate water retention that dangerously lowers blood sodium, and Cushing syndrome from excess cortisol production.¹⁴ These syndromes sometimes show up before the cancer itself is found, so unexplained hormonal or neurological symptoms in a smoker can occasionally be the first clue.

How Lung Cancer Is Staged

Staging tells you how far a cancer has spread, and it is the single biggest factor in deciding treatment and predicting outcomes. NSCLC and SCLC use somewhat different systems.

For NSCLC, doctors use the TNM system, which assesses three things: the size and local extent of the primary tumor (T), whether cancer has reached nearby lymph nodes (N), and whether it has metastasized to distant sites (M). These three factors combine into an overall stage from I to IV.¹⁵ The system is periodically updated by the International Association for the Study of Lung Cancer to reflect better data on how tumor characteristics predict survival.¹⁶

In practical terms:

Stage I: A small tumor confined to the lung with no lymph node involvement. Surgery is the primary treatment and cure rates are highest.
Stage II: A larger tumor or one that has spread to nearby lymph nodes inside the lung. Surgery is still usually an option, sometimes followed by chemotherapy.
Stage III: The cancer has spread to lymph nodes in the center of the chest or has grown into nearby structures. Treatment usually involves a combination of chemotherapy, radiation, and sometimes surgery or immunotherapy.
Stage IV: The cancer has spread to distant organs such as the liver, bones, brain, or adrenal glands. Treatment focuses on controlling the disease and maintaining quality of life rather than cure, though newer therapies have extended survival for many patients.

SCLC has traditionally used a simpler two-stage system: limited stage, where the cancer is confined to one side of the chest and can fit within a single radiation field, and extensive stage, where it has spread beyond that. Recent research suggests the immune landscape differs between these two stages, which may eventually lead to more tailored immunotherapy approaches for each.¹⁷

Causes and Risk Factors Beyond Smoking

Smoking is the dominant cause of lung cancer by a wide margin. The link is not just statistical; it is inscribed in the DNA of the tumors themselves. In smokers’ lung cancers, a specific type of genetic damage called G-to-T transversions appears at three times the rate seen in nonsmokers’ lung cancers, a pattern consistent with the direct action of tobacco smoke carcinogens on DNA.¹⁸ Lung cancer was once so rare that doctors considered it a medical curiosity. The global epidemic followed the mass marketing of cigarettes at the end of the 19th century.¹⁹

But smoking is not the whole story. Residential radon, particulate matter air pollution, and indoor burning of solid fuels all contribute to the global burden of lung cancer, and their relative importance varies by a country’s level of economic development. In wealthier countries, radon exposure accounts for a larger share of the disease burden, while in lower-income settings, solid-fuel burning and outdoor particulate pollution are more significant drivers.²⁰ Projections suggest the death burden from particulate pollution will continue rising in countries like China, India, and Uganda over the coming decade.

Lung Cancer in People Who Never Smoked

Somewhere between 10 and 20 percent of lung cancer cases occur in people who have never smoked, and this population is growing as smoking rates decline in many countries. These cancers are not just rarer versions of smokers’ lung cancer. They are driven by a different set of genetic mutations and behave differently at the molecular level.²¹

The most common driver in never-smokers is a mutation in the epidermal growth factor receptor (EGFR), which acts as a growth switch stuck in the “on” position. In one study of lung adenocarcinomas surgically removed from never-smoking women, EGFR mutations were found in 63 percent of tumors. Altogether, about 79 percent of those tumors harbored a well-known cancer-driving mutation of some kind.²² This is important because several targeted drugs can block EGFR and related pathways effectively, often with fewer side effects than traditional chemotherapy.

A meta-analysis confirmed that never-smokers have significantly higher odds of carrying EGFR and ALK-EML4 mutations compared with people who have smoked, while KRAS mutations are far less common in never-smokers.²³ These findings have reshaped treatment: lung cancer in a never-smoker is now routinely tested for specific mutations upfront, because the right targeted therapy can dramatically change outcomes. The recognition that smoking-associated and nonsmoking-associated lung cancers follow different molecular pathways was identified early in preneoplasia research.³

How Lung Cancer Is Diagnosed

If a chest X-ray or CT scan raises suspicion, the next step is getting a tissue sample. There are several ways to do this, and the choice depends on where the tumor sits. For tumors near the center of the lung, bronchoscopy with endobronchial ultrasound (EBUS) can reach the lesion through the airways. One meta-analysis found that EBUS-guided biopsy of peripheral lung cancers had a sensitivity of about 69 percent, lower than CT-guided needle biopsy through the chest wall (around 94 percent), but with fewer complications.²⁴ In practice, the two methods are complementary rather than competing. For centrally located tumors or lymph node sampling, EBUS can achieve sensitivity above 90 percent.²⁵

Beyond determining whether a mass is cancerous, tissue samples are now routinely tested for the genetic mutations and protein markers that guide treatment, including EGFR mutations, ALK rearrangements, and PD-L1 expression levels. This molecular profiling has become just as important as the traditional microscope-based classification in deciding how to treat a patient.

Liquid biopsy is an emerging approach that analyzes fragments of tumor DNA circulating freely in the blood. It has already proven clinically useful in advanced NSCLC as a less invasive way to detect specific mutations, monitor treatment response, and track how the cancer evolves over time.²⁶ Components like circulating free DNA and circulating tumor cells can reflect characteristics of both the primary tumor and any metastases.²⁷ It is not yet a replacement for tissue biopsy in most situations, but as the technology matures, it may reshape early detection.

Screening with Low-Dose CT

Because lung cancer is often caught late, there has been a long push to find it earlier through screening. Low-dose CT (LDCT) scanning of people at high risk, primarily heavy current or former smokers over a certain age, is now the standard screening method. Evidence accumulated since the late 1990s shows that LDCT can detect lung cancer at an early stage and reduce the chance of dying from it.²⁸

A meta-analysis of screening trials found that LDCT nearly tripled the detection of stage I cancers compared with no screening and reduced lung cancer deaths by about 16 percent. The number needed to screen to prevent one lung cancer death was 265, a figure that compares favorably with screening programs for other cancers.²⁹ Screening does carry downsides: false-positive scans can lead to unnecessary biopsies and anxiety, and there is a small cumulative radiation exposure from annual scans. But for people who meet the eligibility criteria, the mortality benefit outweighs those risks.

One persistent problem is that screening uptake remains low, and not equally distributed. Black individuals and people with lower socioeconomic status are less likely to be screened, contributing to worse outcomes in those groups.³⁰

Racial and Socioeconomic Disparities in Outcomes

Lung cancer does not hit everyone equally, even after accounting for smoking rates and stage at diagnosis. Disparities exist along racial and socioeconomic lines at every step of the pipeline, from who qualifies for screening to who receives the newest treatments.³¹

Among patients with metastatic NSCLC, two-year survival rates differ strikingly by race and ethnicity. Non-Hispanic White and non-Hispanic Asian patients had two-year survival rates around 22 to 23 percent, compared with 15 percent for non-Hispanic Black patients and 17 percent for Hispanic patients. Part of this gap traces to unequal access to immune checkpoint inhibitors, a newer class of drugs that has improved survival in advanced lung cancer. Patients who were younger, not on Medicaid, and living in higher-income or metropolitan areas were all more likely to receive these therapies.³² The biology of lung cancer is complex enough. The added layer of unequal access to screening, timely diagnosis, and modern treatment means that for many patients, their zip code and insurance status shape their prognosis as much as their tumor biology does.

Targeted Therapy and the Shift Toward Precision Treatment

The molecular profiling discussed earlier has not just changed diagnosis. It has opened the door to targeted therapies, drugs designed to block the specific genetic abnormalities powering a particular patient’s tumor. In targeted therapy, drugs home in on specific proteins or gene products that fuel cancer growth, ideally leaving healthy cells largely unharmed.³³ For patients whose tumors carry EGFR mutations, ALK rearrangements, or a growing list of other targetable alterations, these drugs often work better and cause fewer side effects than conventional chemotherapy.

Immune checkpoint inhibitors represent a parallel revolution. These drugs do not target the tumor directly but instead remove the brakes that cancer cells put on the immune system, allowing the body’s own defenses to attack the cancer. PD-L1 expression testing, now a routine part of the diagnostic workup, helps predict which patients are most likely to respond. In one study using EBUS-obtained tissue samples, over 90 percent of specimens were adequate for PD-L1 testing, and more than a third of patients showed high expression levels that would qualify them for first-line immunotherapy.²⁵

The practical implication for patients is that a lung cancer diagnosis today should always include molecular testing of the tumor. Skipping that step means potentially missing a treatment that could work far better than a generic chemotherapy regimen. This is particularly true for never-smokers and patients with adenocarcinoma, whose tumors are especially likely to carry actionable mutations. The landscape of lung cancer treatment has shifted from a one-size-fits-all approach to one where two patients with the same stage of disease might receive entirely different drugs based on what their tumor’s DNA looks like.

1
PubMed Central. AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future
2
PubMed Central. What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients
3
PubMed. Lung cancer preneoplasia
4
PubMed Central. Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: An autopsy study
5
PubMed Central. Pulmonary Neuroendocrine Cells and Small Cell Lung Carcinoma: Immunohistochemical Study Focusing on Mechanisms of Neuroendocrine Differentiation
6
PubMed Central. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts
7
PubMed Central. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes
8
PubMed Central. Primary pulmonary carcinoid tumor: a long-term single institution experience
9
PubMed Central. Management of hemoptysis in patients with lung cancer
10
PLOS ONE. Is symptom-based diagnosis of lung cancer possible? A systematic review and meta-analysis of symptomatic lung cancer prior to diagnosis for comparison with real-time data from routine general practice
11
British Journal of Cancer. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study
12
PubMed Central. Paraneoplastic syndromes associated with lung cancer
13
PubMed Central. Paraneoplastic syndromes in small cell lung cancer
14
PubMed Central. Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance
15
PubMed Central. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams
16
PubMed. Revisions to the TNM Staging of Lung Cancer: Rationale, Significance, and Clinical Application
17
Cancer Research. Abstract 5868: Differential tumor immunity in limited-stage vs extensive-stage small cell lung cancer
18
Carcinogenesis. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke
19
Tobacco Control. The history of the discovery of the cigarette–lung cancer link: evidentiary traditions, corporate denial, global toll
20
PubMed. Disease Burden and Prediction Analysis of Tracheal, Bronchus, and Lung Cancer Attributable to Residential Radon, Solid Fuels, and Particulate Matter Pollution Under Different Sociodemographic Transitions From 1990 to 2030
21
PubMed Central. Lung cancer in never smokers: molecular profiles and therapeutic implications
22
PubMed Central. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR
23
PubMed. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers
24
PubMed Central. Comparison between endobronchial ultrasound-guided transbronchial biopsy and CT-guided transthoracic lung biopsy for the diagnosis of peripheral lung cancer: a systematic review and meta-analysis
25
PubMed Central. EBUS in optimizing non-small cell lung cancer diagnosis and treatment
26
PubMed Central. Liquid biopsy for lung cancer early detection
27
PubMed Central. Cell-free DNA in non-small cell lung cancer
28
PubMed Central. Low-Dose CT Screening for Lung Cancer: Evidence from 2 Decades of Study
29
PubMed Central. Lung Cancer Screening with Low-Dose CT: a Meta-Analysis
30
PubMed Central. Racial and socioeconomic disparities in lung cancer screening in the United States: A systematic review
31
PubMed Central. Disparities in Lung Cancer Screening: A Review
32
PubMed Central. Racial and socioeconomic disparities in survival among patients with metastatic non-small cell lung cancer
33
PubMed Central. Recent advances in non-small cell lung cancer targeted therapy; an update review